| Mrs Joann Whitfield Shiver, LPN | |
|
139 12th St, Apalachicola, FL 32320-2110 | |
| (850) 653-2111 | |
| Not Available |
| Full Name | Mrs Joann Whitfield Shiver |
|---|---|
| Gender | Female |
| Speciality | Licensed Practical Nurse |
| Location | 139 12th St, Apalachicola, Florida |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093787665 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 164W00000X | Licensed Practical Nurse | PN1026271 (Florida) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Joann Whitfield Shiver, LPN 139 12th St, Apalachicola, FL 32320-2110 Ph: (850) 653-2111 | Mrs Joann Whitfield Shiver, LPN 139 12th St, Apalachicola, FL 32320-2110 Ph: (850) 653-2111 |
News Archive
The 24-hour internal clock controls many aspects of human behavior and physiology, including sleep, blood pressure, and metabolism. Disruption in circadian rhythms leads to increased incidence of many diseases, including metabolic disease and cancer. Each cell of the body has its own internal timing mechanism, which is controlled by proteins that keep one another in check.
The latest research shows that since the 2006 introduction of routine inoculation against rotavirus - a leading cause of diarrhea in infants and young children - almost 65,000 fewer American children have been hospitalized and about $278 million in healthcare costs have been saved.
Annual heart disease and stroke rates in China will rise by up to 73 percent by 2030, given an aging population and other increased risk factors, without policies and prevention efforts aimed at controlling blood pressure and smoking, according to research from Columbia University Medical Center published in Circulation: Cardiovascular Quality and Outcomes, an American Heart Association journal.
Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for its angiotensin II receptor blocker (ARB) Micardis® (telmisartan) Tablets 80 mg for reduction of the risk of myocardial infarction, stroke, or death from cardiovascular causes in patients 55 years of age or older at high risk of developing major cardiovascular events who are unable to take angiotensin-converting enzyme (ACE) inhibitors.(1) MICARDIS is the most studied ARB in this high-risk patient population and has been commercially available to treat hypertension (high blood pressure) since its approval in 1998.
A new study, published in the July issue of Advances in Therapy, revealed that a novel saw palmetto extract, SPET-085, is as effective as finasteride, the standard prescription drug therapy, in blocking the critical enzyme that leads to benign prostatic hyperplasia.
› Verified 2 days ago
Mrs. Gloria Tindell Chambers, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 139 12th St, Apalachicola, FL 32320 Phone: 850-653-2111 | |
Mrs. April Hogan Rester, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 139 12th St, Apalachicola, FL 32320 Phone: 850-653-2111 |